Appili Therapeutics Valuation
| APLI Stock | CAD 0.02 0.01 20.00% |
Appili Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Appili Therapeutics from analyzing the firm fundamentals such as Return On Equity of -9.39, operating margin of (88.64) %, and Shares Outstanding of 121.27 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Appili Therapeutics' valuation include:
Price Book 1.3981 | Enterprise Value | Enterprise Value Ebitda 37.4175 | Price Sales 11.7557 | Forward PE 2.3776 |
Overvalued
Today
Please note that Appili Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Appili Therapeutics is based on 3 months time horizon. Increasing Appili Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Appili Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Appili Stock. However, Appili Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.02 | Real 0.0189 | Hype 0.02 |
The intrinsic value of Appili Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Appili Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Appili Therapeutics helps investors to forecast how Appili stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Appili Therapeutics more accurately as focusing exclusively on Appili Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Appili Therapeutics' intrinsic value based on its ongoing forecasts of Appili Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Appili Therapeutics' closest peers.
Appili Therapeutics Cash |
|
About Appili Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Appili Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Appili Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Appili Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Appili Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Appili Therapeutics. We calculate exposure to Appili Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Appili Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 115.5 K | 109.7 K | |
| Pretax Profit Margin | (23.35) | (24.52) | |
| Operating Profit Margin | (1.71) | (1.80) | |
| Net Loss | (23.52) | (24.69) | |
| Gross Profit Margin | 0.88 | 0.78 |
Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.